Ifosfamide or trofosfamide in patients with intraocular lymphoma: Final report

Authors:

Abstract
2030 Background: This abstract reports the long-term results of intraocular lymphoma (IOL) patients treated with ifosfamide (IFO) or trofosfamide (TRO). Methods: We previously reported the efficacy of intravenous IFO and oral TRO in a single center prospective study on 10 patients with IOL. IFO was given at a dose of 1,500 (≥65 years) or 2,000 (<65 years) mg/m²/day on days 1–3 and TRO at a dose of 150 and 400 mg/day (continuous or intermittent administration). Remission rate, progression-free survival (PFS), overall survival (OS) and long-term toxicity were evaluated in this follow-up analysis. Results: All patients responded to first treatment with IFO or TRO, including nine complete remissions and one partial remission. Median PFS from the first treatment with IFO or TRO was 18 (range, 7–36) months. Seven patients relapsed: five in the eye and two in the brain. Four patients were retreated with IFO or TRO on relapse, three of whom responded. Median OS was 32 (range, 7–37+) months. Acute toxicity was mainly hematologic. No long-term toxicity was observed in patients treated with IFO or TRO alone. Conclusions: Response rates to IFO and TRO are high with tolerable toxicity. Combination treatment of IFO/TRO with other cytostatics is warranted to improve long-term disease control. No significant financial relationships to disclose.